Resilience is a North American CDMO focused on delivering high-quality, scalable manufacturing solutions for advanced therapies. With capabilities spanning biologics drug substance, cell-based therapies, and aseptic drug product manufacturing for both small and large molecules, the company partners with leading biopharma organizations to accelerate the delivery of complex medicines through a digital-first approach that leverages cloud-based systems, advanced AI, and enhanced production visibility. Resilience has four facilities across the U.S. and Canada that provide cell and gene therapy, biologics, nucleic acids, and vaccine research and development to their customers. Their biologics services include mAbs, enzymes, fusion proteins, bispecifics, noncytotoxic conjugation, and recombinant proteins.
